Buphenyl and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with Buphenyl (sodium phenylbutyrate).
Sodium Phenylbutyrate Food
Moderate Food Interaction
ADJUST DOSING INTERVAL: Coadministration with a high-fat meal may reduce the rate and extent of absorption of sodium phenylbutyrate. When a single 3 g-1 g dose of sodium phenylbutyrate-taurursodiol (sodium phenylbutyrate-ursodoxicoltaurine) was administered to healthy volunteers in the presence of a high-fat, high-calorie meal (approximately 800 to 1000 calories; 500 to 600 calories from fat, 250 calories from carbohydrate, 150 calories from protein), sodium phenylbutyrate peak plasma concentration (Cmax) decreased by 75% and systemic exposure (AUC) decreased by 55%. The Cmax for taurursodiol was not significantly affected, but AUC was increased by 46%. The clinical significance of these changes has not been established. In premarketing studies, patients were advised to take the drug before a meal.
MANAGEMENT: The prescribing information recommends administration of sodium phenylbutyrate-taurursodiol before a meal or snack, particularly in patients of low body weight (less than 70 kg).
References (2)
- (2022) "Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol)." Amylyx Pharmaceuticals, 1
- (2022) "Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine)." Innomar Strategies Inc.
Switch to consumer interaction data
Buphenyl drug interactions
There are 34 drug interactions with Buphenyl (sodium phenylbutyrate).
Buphenyl disease interactions
There are 3 disease interactions with Buphenyl (sodium phenylbutyrate) which include:
More about Buphenyl (sodium phenylbutyrate)
- Buphenyl consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- Drug class: urea cycle disorder agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Ravicti
Ravicti (glycerol phenylbutyrate) is used to treat urea cycle disorders. Includes Ravicti side ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Sodium phenylbutyrate
Sodium phenylbutyrate systemic is used for urea cycle disorders
Glycerol phenylbutyrate
Glycerol phenylbutyrate systemic is used for urea cycle disorders
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.